

Gavin P Dunn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2061046/publications.pdf>

Version: 2024-02-01

101
papers

20,619
citations

87888

38
h-index

43889

91
g-index

103
all docs

103
docs citations

103
times ranked

29157
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	9.6	29
2	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
3	Applied cancer immunogenomics in glioblastoma. , 2022, , 19-38.		0
4	Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. <i>Cancer Discovery</i> , 2022, 12, 154-171.	9.4	34
5	Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA. <i>Theranostics</i> , 2022, 12, 362-378.	10.0	21
6	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	2.2	5
7	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vda002.	0.7	3
8	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	7.0	20
9	Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. <i>Genome Medicine</i> , 2022, 14, 49.	8.2	37
10	Considerations for personalized neoantigen vaccination in Malignant glioma. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114312.	13.7	13
11	Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. <i>Neurosurgery</i> , 2021, 88, E49-E59.	1.1	8
12	A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53.	2.9	159
13	Photosensitivity Reaction From Operating Room Lights After Oral Administration of 5-Aminolevulinic Acid for Fluorescence-Guided Resection of a Malignant Glioma. <i>Cureus</i> , 2021, 13, e13442.	0.5	0
14	Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2326-2339.	7.0	16
15	39607 Mapping the Draining Lymph Nodes in Central Nervous System Malignancies. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 37-37.	0.6	0
16	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. <i>Neurosurgery</i> , 2021, 89, 129-132.	1.1	5
17	Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. <i>Genome Medicine</i> , 2021, 13, 56.	8.2	34
18	Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2070-TPS2070.	1.6	1

#	ARTICLE	IF	CITATIONS
19	A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-17, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.. Journal of Clinical Oncology, 2021, 39, 2040-2040.	1.6	2
20	Personalized DNA neoantigen vaccine in combination with plasmid IL-12 for the treatment of a patient with anaplastic astrocytoma.. Journal of Clinical Oncology, 2021, 39, e14561-e14561.	1.6	0
21	Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery. Journal of Neurosurgery, 2021, 135, 855-861.	1.6	4
22	Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary, 2021, 24, 359-373.	2.9	12
23	Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms. Biomarker Insights, 2021, 16, 117727192110066.	2.5	6
24	Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma. Neuro-Oncology Advances, 2021, 3, vdab081.	0.7	1
25	Unique challenges for glioblastoma immunotherapyâ€”discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
26	Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma. Nature Communications, 2021, 12, 6321.	12.8	16
27	Serving on the Navy's Hospital Ships During the Response to COVID-19: Perspective from Two Deployed Missouri Physicians. Missouri Medicine, 2021, 118, 110-112.	0.3	0
28	777â€¦Personalized DNA vaccine in combination with plasmid encoded IL-12 for the treatment of a patient with anaplastic astrocytoma. , 2021, 9, A812-A812.		0
29	Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa126.	0.7	27
30	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirusâ€”Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	7.0	163
31	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
32	Cancers from Novel <i>Pole</i>-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.9	14
33	GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Scientific Reports, 2020, 10, 9027.	3.3	20
34	Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro-Oncology, 2020, 22, 1276-1288.	1.2	51
35	TERT, a promoter of CNS malignancies. Neuro-Oncology Advances, 2020, 2, vdaa025.	0.7	22
36	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438.	1.2	37

#	ARTICLE	IF	CITATIONS
37	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	1.2	131
38	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363.	1.2	1
39	Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. <i>Journal of Neurosurgery</i> , 2020, , 1-10.	1.6	20
40	An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments. <i>Missouri Medicine</i> , 2020, 117, 45-49.	0.3	1
41	SURG-12. PREDICTORS OF SURVIVAL AND UTILITY OF INTRAOPERATIVE MRI FOR RESECTION OF GRADE II ASTROCYTOMAS AND OLIGODENDROGLIOMAS: A MULTICENTER ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii205-ii206.	1.2	0
42	IMMU-53. CHARACTERIZATION OF THE GENOMIC AND IMMUNOLOGICAL DIVERSITY OF MALIGNANT BRAIN TUMORS THROUGH MULTI-SECTOR ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii116-ii116.	1.2	0
43	IMMU-26. UNRAVELING ANTIGEN PRESENTATION IN CENTRAL NERVOUS SYSTEM ANTI-TUMOR IMMUNITY. <i>Neuro-Oncology</i> , 2020, 22, ii110-ii110.	1.2	0
44	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>Oncimmunology</i> , 2019, 8, e1561106.	4.6	50
45	Characterization and validation of an intrafraction motion management system for masked-based radiosurgery. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 21-26.	1.9	13
46	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii97.	1.2	0
47	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2032-2032.	1.6	33
48	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	1.8	13
49	Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002444.	1.2	16
50	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186.	7.0	402
51	Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. <i>Cell Reports</i> , 2018, 22, 512-522.	6.4	74
52	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 472-483.	1.2	42
53	Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. <i>Scientific Reports</i> , 2018, 8, 6553.	3.3	55
54	Direct puncture Onyx embolization of a large calvarial metastasis with intracranial extension: Case report. <i>Interventional Neuroradiology</i> , 2018, 24, 220-224.	1.1	1

#	ARTICLE	IF	CITATIONS
55	IMMU-05. LATE EFFECTS OF INTRACRANIAL RADIATION INDUCES RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE THERAPY THAT IS PARTIALLY REVERSIBLE WITH CSF-1R INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, vi122-vi122.	1.2	0
56	A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nature Genetics</i> , 2018, 50, 1735-1743.	21.4	62
57	Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. <i>Radiotherapy and Oncology</i> , 2018, 128, 266-273.	0.6	48
58	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119.	1.8	34
59	Applied Cancer Immunogenomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 125-130.	2.0	16
60	Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	130
61	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
62	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 71, 169-176.	1.5	16
63	Targeting Neoantigens in Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 165-176.	1.1	24
64	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 34.	6.5	21
65	Genomic profile of human meningioma cell lines. <i>PLoS ONE</i> , 2017, 12, e0178322.	2.5	44
66	Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347.	1.8	16
67	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	1.8	100
68	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1230-1236.	9.4	242
69	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , 2016, 4, 1007-1015.	3.4	84
70	Genomic landscape of intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 525-535.	1.6	104
71	High incidence of TERT mutation in brain tumor cell lines. <i>Brain Tumor Pathology</i> , 2016, 33, 222-227.	1.7	26
72	Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2080-TPS2080.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS6110-TPS6110.	1.6	5
74	Principles of immunology and its nuances in the central nervous system: Fig. 1.. Neuro-Oncology, 2015, 17, vii3-vii8.	1.2	28
75	A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Reports, 2015, 11, 1809-1821.	6.4	82
76	Surgical Revascularization in North American Adults with Moyamoya Phenomenon: Long-Term Angiographic Follow-up. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1597-1608.	1.6	26
77	Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1000-1007.	0.8	80
78	The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2015, 13, 502-509.	3.4	26
79	Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, TPS2077-TPS2077.	1.6	2
80	Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. Frontiers in Oncology, 2014, 4, 126.	2.8	127
81	In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1102-1107.	7.1	42
82	Three-dimensional brain surface visualization for epilepsy surgery of focal cortical dysplasia. Journal of Clinical Neuroscience, 2014, 21, 1230-1232.	1.5	2
83	A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease. Clinical Cancer Research, 2014, 20, 2873-2884.	7.0	84
84	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	28.9	3,979
85	Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1. Journal of Neurosurgery, 2013, 118, 142-148.	1.6	65
86	From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical Focus, 2013, 34, E2.	2.3	59
87	Cancer Immunoediting in Malignant Glioma. Neurosurgery, 2012, 71, 201-223.	1.1	79
88	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	5.9	463
89	Dual Ipsilateral Craniotomies Through a Single Incision for the Surgical Management of Multiple Intracranial Aneurysms. World Neurosurgery, 2012, 77, 502-506.	1.3	8
90	Surgical Treatment of a Large Fusiform Distal Anterior Cerebral Artery Aneurysm With In Situ End-to-Side A3A3 Bypass Graft and Aneurysm Trapping: Case Report and Review of the Literature. Neurosurgery, 2011, 68, E587-E591.	1.1	23

#	ARTICLE	IF	CITATIONS
91	Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia. Head and Neck, 2008, 30, 267-272.	2.0	9
92	Mycotic Pseudoaneurysm of the Internal Maxillary Artery. JAMA Otolaryngology, 2007, 133, 402.	1.2	6
93	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immunity, 2007, 7, 12.	3.2	102
94	Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. Advances in Immunology, 2006, 90, 1-50.	2.2	689
95	Interferons, immunity and cancer immunoediting. Nature Reviews Immunology, 2006, 6, 836-848.	22.7	1,312
96	IFN Unresponsiveness in LNCaP Cells Due to the Lack of <i>JAK1</i> Gene Expression. Cancer Research, 2005, 65, 3447-3453.	0.9	161
97	Interferon- β and Cancer Immunoediting. Immunologic Research, 2005, 32, 231-246.	2.9	123
98	A critical function for type I interferons in cancer immunoediting. Nature Immunology, 2005, 6, 722-729.	14.5	516
99	The Three Es of Cancer Immunoediting. Annual Review of Immunology, 2004, 22, 329-360.	21.8	2,422
100	The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 2004, 21, 137-148.	14.3	2,486
101	Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002, 3, 991-998.	14.5	4,290